These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 26035328)
61. Cytotoxic chemotherapy and the evolution of cellular and viral resistance to antiretroviral therapy in HIV- infected individuals with lymphoma. McFaul K; Liptrott N; Cox A; Martin P; Egan D; Owen A; Kelly S; Karolia Z; Shaw K; Bower M; Boffito M HIV Clin Trials; 2016 Sep; 17(5):197-203. PubMed ID: 27454119 [TBL] [Abstract][Full Text] [Related]
62. Basis of selection of first and second line highly active antiretroviral therapy for HIV/AIDS on genetic barrier to resistance: a literature review. Katusiime C; Ocama P; Kambugu A Afr Health Sci; 2014 Sep; 14(3):679-81. PubMed ID: 25352888 [TBL] [Abstract][Full Text] [Related]
63. Addition of Etravirine Does Not Enhance the Initial Decline of HIV-1 RNA in Treatment-Experienced Patients Receiving Raltegravir. Flandre P; Marcelin AG; Calvez V; J Acquir Immune Defic Syndr; 2017 Aug; 75(4):448-454. PubMed ID: 28653971 [TBL] [Abstract][Full Text] [Related]
64. Impact of adding raltegravir to antiretroviral regimens in patients with blood viral suppression but persistent seminal viral shedding. Fiore JR; Zoboli F; Di Stefano M; Faleo G; Fasano M; Santantonio TA AIDS; 2016 Apr; 30(7):1144-6. PubMed ID: 27028146 [No Abstract] [Full Text] [Related]
65. Four-class drug-resistant HIV-1 subtype C in a treatment experienced individual on dolutegravir-based antiretroviral therapy in Botswana. Seatla KK; Avalos A; Moyo S; Mine M; Diphoko T; Mosepele M; Gaolatlhe T; Rowley CF; Ramaabya D; Jarvis JN; Kasvosve I; Gaseitsiwe S AIDS; 2018 Aug; 32(13):1899-1902. PubMed ID: 29894383 [TBL] [Abstract][Full Text] [Related]
66. An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study. Galli L; Poli A; Muccini C; Galizzi N; Danise A; Spagnuolo V; Gianotti N; Carini E; Lazzarin A; Castagna A Infect Dis (Lond); 2018 Mar; 50(3):220-222. PubMed ID: 28891371 [No Abstract] [Full Text] [Related]
67. Initial treatment response among HIV subtype F infected patients who started antiretroviral therapy based on integrase inhibitors. Cid-Silva P; Margusino-Framiñán L; Balboa-Barreiro V; Martín-Herranz I; Castro-Iglesias Á; Pernas-Souto B; Llibre JM; Poveda E AIDS; 2018 Jan; 32(1):121-125. PubMed ID: 29112068 [TBL] [Abstract][Full Text] [Related]
68. Do resistance patterns vary between different FTC containing drug regimens? Chacko L; Chamberlain F; Mandalia S; Nelson M J Infect; 2014 May; 68(5):503-5. PubMed ID: 24513393 [No Abstract] [Full Text] [Related]
69. Reporting on the prevalence of antiretroviral drug resistance in a regional HIV population over 20 years: a word of caution. Gill VC; Lynch T; Ramazani S; Krentz HB Antivir Ther; 2017; 22(4):277-286. PubMed ID: 27805572 [TBL] [Abstract][Full Text] [Related]
70. Similar short-term efficacy of antiretroviral therapy in patients infected with HIV B and non-B subtype strains in france. Bouchaud O; Le Moing V; Simon F; Ngo Van P; Perre P; Hocqueloux L; Lebouche B; Carret S; Spire B J Acquir Immune Defic Syndr; 2011 Feb; 56(2):e67-9. PubMed ID: 21233637 [No Abstract] [Full Text] [Related]
71. Long-term control of viral replication in a Group O, human immunodeficiency virus type 1-infected individual. Buckheit RW; Sexauer SB; Sedaghat AR; Wilke CO; Laeyendecker O; Basseth CR; Blankson JN AIDS Res Hum Retroviruses; 2014 Jun; 30(6):511-3. PubMed ID: 24798496 [No Abstract] [Full Text] [Related]
72. Genotypic Methods for HIV Drug Resistance Monitoring: The Opportunities and Challenges Faced by China. Zuo L; Peng K; Hu Y; Xu Q Curr HIV Res; 2019; 17(4):225-239. PubMed ID: 31560290 [TBL] [Abstract][Full Text] [Related]
73. Raltegravir blocks the infectivity of red-fluorescent-protein (mCherry)-labeled HIV-1 Ogata-Aoki H; Higashi-Kuwata N; Hattori SI; Hayashi H; Danish M; Aoki M; Shiotsu C; Hashiguchi Y; Hamada A; Kobayashi H; Ihn H; Okada S; Mitsuya H Antiviral Res; 2018 Jan; 149():78-88. PubMed ID: 28893602 [TBL] [Abstract][Full Text] [Related]
74. The Impact of HIV-1 Drug Escape on the Global Treatment Landscape. Collier DA; Monit C; Gupta RK Cell Host Microbe; 2019 Jul; 26(1):48-60. PubMed ID: 31295424 [TBL] [Abstract][Full Text] [Related]
75. HIV-1 subtype and virological response to antiretroviral therapy: acquired drug resistance. Soares EA; Santos AF; Soares MA Clin Infect Dis; 2012 Mar; 54(5):738-9. PubMed ID: 22144544 [No Abstract] [Full Text] [Related]
76. First-line HIV therapy shall not fail. Boucher C; Vella S Lancet HIV; 2016 Mar; 3(3):e108-9. PubMed ID: 26939732 [No Abstract] [Full Text] [Related]
77. British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. Asboe D; Aitken C; Boffito M; Booth C; Cane P; Fakoya A; Geretti AM; Kelleher P; Mackie N; Muir D; Murphy G; Orkin C; Post F; Rooney G; Sabin C; Sherr L; Smit E; Tong W; Ustianowski A; Valappil M; Walsh J; Williams M; Yirrell D; HIV Med; 2012 Jan; 13(1):1-44. PubMed ID: 22171742 [No Abstract] [Full Text] [Related]
78. Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). Fogel JM; Wang L; Parsons TL; Ou SS; Piwowar-Manning E; Chen Y; Mudhune VO; Hosseinipour MC; Kumwenda J; Hakim JG; Chariyalertsak S; Panchia R; Sanne I; Kumarasamy N; Grinsztejn B; Makhema J; Pilotto J; Santos BR; Mayer KH; McCauley M; Gamble T; Bumpus NN; Hendrix CW; Cohen MS; Eshleman SH J Infect Dis; 2013 Nov; 208(10):1624-8. PubMed ID: 23908493 [TBL] [Abstract][Full Text] [Related]